For Q1 FY2026 ended March 31, 2026, Bausch Health reported revenue of $2.524 billion, up 11.7% year-over-year. Net loss was $1.423 billion, a significant decline from a small loss in the prior year, driven by an operating loss of $950 million. Diluted EPS was -$3.82. The company had $1.299 billion in cash, negative equity of $2.059 billion, and long-term debt of $20.764 billion.
•Revenue grew 11.7% YoY to $2.524 billion.
•Net loss widened to $1.423 billion from a prior-year loss of $58 million.
•Operating loss was $950 million, compared to a prior-year loss of $174 million.
•Long-term debt stood at $20.764 billion with negative equity of $2.059 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Bausch Health Companies is a diversified specialty pharmaceutical and medical device company. Its business is organized into five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.
The company sells its products globally. Formerly known as Valeant Pharmaceuticals International, Inc., the company rebranded as Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company. It develops, manufactures, and markets products across several therapeutic areas, including gastroenterology, hepatology, neurology, dermatology, and eye health. The company also offers generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, and aesthetic medical devices. Its business is organized into five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment focuses on gastrointestinal products, while Bausch + Lomb is a leading eye health brand. Solta Medical provides aesthetic devices, and the Diversified segment includes neurology and dermatology products. The International segment covers markets outside the U.S. and Canada.
Where is Bausch Health (BHC) listed and in which currency?
Bausch Health Companies Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol BHC. Its shares are traded in U.S. dollars (USD). The company is headquartered in Laval, Canada, but its primary stock listing is on a U.S. exchange, making it accessible to investors globally. The use of USD for trading means that investors outside the U.S. may be exposed to currency exchange rate fluctuations when converting their local currency to dollars.
What sector and industry does Bausch Health (BHC) operate in?
Bausch Health Companies Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects the company's focus on developing and manufacturing both branded specialty pharmaceuticals and generic drugs. Unlike large-cap pharmaceutical companies that primarily develop novel drugs, Bausch Health has a diversified portfolio that includes prescription medications, over-the-counter products, and medical devices. Its specialty areas include gastroenterology, hepatology, neurology, dermatology, and eye health, while its generic segment offers cost-effective alternatives to branded drugs.
Where is Bausch Health (BHC) headquartered and what markets does it serve?
Bausch Health Companies Inc. is headquartered in Laval, Canada, a city near Montreal in the province of Quebec. The company sells its products globally, with a significant presence in the United States, Canada, and international markets. Its global reach is supported by the International segment, which manages operations outside North America. The company's products are distributed through various channels, including healthcare professionals, hospitals, pharmacies, and direct-to-consumer platforms. Despite being a Canadian company, Bausch Health's primary listing on the NYSE and its reporting currency in USD underscore its strong ties to the U.S. market.
What is the business model of Bausch Health (BHC) and how does it generate revenue?
Bausch Health generates revenue through the development, manufacturing, and marketing of a wide range of pharmaceutical and medical device products. Its business is organized into five segments: Salix (gastrointestinal products), International (markets outside the U.S. and Canada), Solta Medical (aesthetic devices), Diversified (neurology, dermatology, and other products), and Bausch + Lomb (eye health). The company earns money by selling prescription drugs, over-the-counter medications, generic pharmaceuticals, dentistry products, and aesthetic devices. Key revenue drivers include the Salix segment's gastroenterology portfolio, the Bausch + Lomb eye health franchise, and the Solta Medical aesthetic devices. The company also benefits from its diversified product mix, which reduces reliance on any single therapeutic area.